On May 18, 2020 Celleron reported the launch of the University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer, led by Prof. David Kerr (Radcliffe Department of Medicine, University of Oxford) and Prof. Li Yang (Sichuan University) (Press release, Celleron, MAY 18, 2020, View Source [SID1234560784]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Over the next 5 years, this new international collaboration seeks to develop an integrated cancer plan with a focus on gastrointestinal cancer, underpinned by high quality basic, translational and clinical cancer research.

The intention is to develop one team based across two sites, with an operating and governance system that will drive the exchange of ideas, which is crucial to academic development and alleviating the burden that cancer places on society across the world.

The Centre will seek to build a portfolio of multi-disciplinary teams drawing from both organizations. These teams and their projects will enable scientists and clinicians to learn from each other and apply their expertise for the benefit of cancer patients in both nations. The establishment of a bilateral researcher exchange program will drive the delivery of these.

Professor David Kerr, Co-Director of the University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer and CMO of Celleron Therapeutics, commented,

"The idea behind personalised cancer medicine is both simple and powerful: delivering the right treatment to the right patient at the right time. Our aim is to radically alter the way cancer is managed, saving lives by focusing on the individual"

Professor Nick La Thangue, CEO of Celleron Therapeutics, commented,

"Cancer remains a devastating and clinically unmet disease. It is very pleasing that our leadership team can contribute to international partnerships between leading universities and hospitals aiming to improve treatment of the disease".